EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary

EXOZYMES INC. reported results for the quarter and six-month period ended June 30, 2026, showing no revenue and a net loss of $5.25M for the six-month period as the company increased R&D activity and completed equity financings to support near-term operations.

Financial Highlights

• Revenue was $0 for 2Q 2026 and for the six months ended June 30, 2026 (no operating income reported).
• Net income (loss) was $(5,248,861) for the six months ended June 30, 2026, versus $(4,216,707) in the prior-year period (loss widened (24.5%) year over year).
• Diluted earnings per share: Not reported in the filing and therefore omitted.

Business Highlights

• Capital raise & liquidity: Completed public and registered direct offerings in June 2026, providing net proceeds to support near-term operations.
• R&D expansion: Research and development activity increased materially, driven by new hires, higher laboratory expenditures, increased stock-based compensation and reduced grant funding.
• Grant and partnership momentum: Secured an NIH BioClick grant and a $3M portion of an NSF CFIRE industrial partnership to support work on the company’s cell-free platform.
• Operational scale-up: The company hired additional staff and invested in lab equipment while scaling back certain IT and investor relations initiatives to reallocate resources.
• Going concern & funding plan: Management disclosed substantial doubt about the company’s 12-month runway and is pursuing additional grants, licensing opportunities and potential financings.

Original SEC Filing: EXOZYMES INC. [ EXOZ ] - 10-Q - Aug. 13, 2026